These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 6432400

  • 41. Aminoglycosides and renal magnesium homeostasis in humans.
    von Vigier RO, Truttmann AC, Zindler-Schmocker K, Bettinelli A, Aebischer CC, Wermuth B, Bianchetti MG.
    Nephrol Dial Transplant; 2000 Jun; 15(6):822-6. PubMed ID: 10831634
    [Abstract] [Full Text] [Related]

  • 42. Bacterial cyanogenesis occurs in the cystic fibrosis lung.
    Sanderson K, Wescombe L, Kirov SM, Champion A, Reid DW.
    Eur Respir J; 2008 Aug; 32(2):329-33. PubMed ID: 18480103
    [Abstract] [Full Text] [Related]

  • 43. Ceftazidime - a significant advance in the treatment of cystic fibrosis.
    David TJ, Phillips BM, Connor PJ.
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():337-40. PubMed ID: 6352639
    [Abstract] [Full Text] [Related]

  • 44. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis.
    Bosso JA, Bonapace CR, Flume PA, White RL.
    Pharmacotherapy; 1999 May; 19(5):620-6. PubMed ID: 10331825
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
    Smith BR.
    Clin Pharm; 1984 May; 3(4):373-85. PubMed ID: 6380902
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Cellular proteolysis and systemic inflammation during exacerbation in cystic fibrosis.
    Ionescu AA, Nixon LS, Shale DJ.
    J Cyst Fibros; 2004 Dec; 3(4):253-8. PubMed ID: 15698944
    [Abstract] [Full Text] [Related]

  • 50. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A, García-Castillo M, Maiz L, Lamas A, Baquero F, Cantón R.
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y, Kim TH, Tao X, Kinzig M, Landersdorfer CB, Drescher SK, Sutaria DS, Moya B, Holzgrabe U, Sörgel F, Bulitta JB.
    Eur J Pharm Sci; 2018 Oct 15; 123():416-428. PubMed ID: 30076955
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
    Reid DW, Latham R, Lamont IL, Camara M, Roddam LF.
    J Cyst Fibros; 2013 Dec 15; 12(6):688-99. PubMed ID: 23706827
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Ceftazidime treatment of chronic Pseudomonas infection in patients with cystic fibrosis.
    Fluge G, Digranes A, Michalsen H, Stiris T, Bergan T, Qvigstad EK.
    Eur J Respir Dis; 1987 Oct 15; 71(4):239-43. PubMed ID: 3319661
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.